WhayneTFJr. Assessment of low-density lipoprotein targets. Angiology. 2013;64(6):411–416.
2.
TaylorFHuffmanMDMacedoAF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816. doi:10.1002/14651858.CD004816.pub5.
3.
AllaVMAgrawalVDenazarethAMohiuddinSRavillaSRendellM. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. Drugs. 2013;73(10):1025–1054.
4.
BarterPJCaulfieldMErikssonM. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–2122.
5.
RidkerPMPaynterNPRifaiNGazianoJMCookNR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–2251.
6.
FerréNTousMPaulA. Paraoxonase Gln-Arg(192) and Leu-Met(55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem. 2002;35(3):197–203.
7.
Otocka-KmiecikAMikhailidisDPNichollsSJDavidsonMRyszJBanachM. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?Prog Lipid Res. 2012;51(4):314–324.
8.
MikhailidisDPElisafM, RizzoM, et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
9.
CollBAlonso-VillaverdeCJovenJ. Monocyte chemoattractant protein-1 and atherosclerosis: is there room for an additional biomarker?Clin Chim Acta. 2007;383(1-2):21–29.
10.
JovenJSimóJMVilellaECampsJEspinelEVillabonaC. Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. Clin Chem. 1995;41(6):908–913.
11.
MatasCCabréMLa VilleA. Limitations of the Friedewald formula for estimating low-density lipoprotein cholesterol in alcoholics with liver disease. Clin Chem. 1994;40(3):404–406.
12.
Rubiés-PratJReverterJLSentíM. Calculated low-density lipoprotein cholesterol should not be used for management of lipoprotein abnormalities in patients with diabetes mellitus. Diabetes Care. 1993;16(8):1081–1086.
13.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497.
14.
de CordovaCMde CordovaMM. A new accurate, simple formula for LDL-cholesterol estimation based on directly measured blood lipids from a large cohort. Ann Clin Biochem. 2013;50(1):13–19.
15.
GómezFCampsJSimóJMFerréNJovenJ. Agreement study of methods based on the elimination principle for the measurement of LDL- and HDL-cholesterol compared with ultracentrifugation in patients with liver cirrhosis. Clin Chem. 2000;46(8):1188–1191.
16.
SimóJMCastellanoIFerréNJovenJCampsJ. Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. Clin Chem. 1998;44(6):1233–1241.
17.
MoraSRifaiNBuringJERidkerPM. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009;55(5):888–894.
